Michael Leach,Laurence Harbige,Dieter Riddall,Karl Franzmann
申请号：
US12811884
公开号：
US08691818B2
申请日:
2009.01.16
申请国别(地区):
US
年份:
2014
代理人:
摘要：
Compounds of general structure in which X and Y are each N or C with at least one of X and Y being N Z is a single bond or an optionally substituted linking group R1 is hydrogen or a substituent group R2 is amino or a substituent group N* is amino when RI is hydrogen or ═NH when R1 is a substituent group or N* is a group NRaRb where Ra and Rb are independently H or an alkyl group or N* is an optionally substituted piperazinyl ring and A is an optionally substituted heterocyclic or carbocyclic ring system which may be linked to the triazo/diazo ring through R2 to form a fused multicyclic ring are indicated as suitable for treatment of disorders in mammals that are susceptible to sodium channel blockers and antifolates, and particularly disorders such epilepsy, multiple sclerosis, glaucoma and uevitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimers disease, Parkinsons disease, chronic inflammatory pain, neuropathic pain, migraine, bipolar disorder, mood, anxiety and cognitive disorders, schizophrenia and trigeminal autonomic cephalalgias for treatment of mammalian cancers and for treatment of malaria.
